
Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
過去 90 日內有 1 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Director
註冊以查看完整訊號動態
Exelixis 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Exelixis你 | 1 | 1 | -100% | 1 | 31 |
Associate GPO Strategic Partner Marketing and Operations Director
查看招聘Alameda, CA · 上星期
Associate Director, Stability Management
查看招聘Alameda, CA · 2星期前
PSC Operations Management Director
查看招聘Alameda, CA · 2星期前
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
ADG126與抗PD-1聯合治療MSS結直腸癌顯示良好效果。更高劑量和頻率展現臨床效益,計劃在2024年擴大試驗。
Exelixis將在分析師降級後發布第三季度業績。生物科技公司必須在上一季度數據喜憂參半後交出亮眼成績。
FirstBio Therapeutics成立科學諮詢委員會,由全球製藥研發領導者組成,推進FB849免疫療法和神經退化性疾病管線開發。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Exelixis 業務、市場及增長訊號的快速解答。
